Premium
Proteomic Analysis Reveals that EPHX1 Contributes to 5‐Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line
Author(s) -
Sun Rui,
Dong Chengyong,
Li Rui,
Chu Hongwei,
Liu Jianhui,
Hao Dingjun,
Zhang Lihua,
Zhao Baofeng,
Wang Liming,
Zhang Yukui
Publication year - 2020
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201900080
Subject(s) - clonogenic assay , hepatocellular carcinoma , proteomics , drug resistance , membrane protein , western blot , cancer research , cell culture , biology , doxorubicin , chemotherapy , cell , medicine , biochemistry , membrane , genetics , microbiology and biotechnology , gene
Purpose The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure. A deeper understanding of the drug resistance mechanism of tumor cells is very significant for improving the clinical prognosis of patients with HCC. Experimental Design In this study, proteomic studies on the composition of 5‐fluorouracil (5‐Fu) resistant Bel/5Fu cell line and its parent Bel7402 cell line by using an ionic liquid assisted proteins extraction method with the advantage of extracting plasma membrane proteins to a wider extent are performed. Then the expression level and function of differentially expressed plasma membrane proteins are verified. Results In total, 25 plasma membrane proteins are shown differentially expressed in Bel/5Fu compared with Bel7402. Western blot analysis results further confirmed that the EPHX1 PLIN2 RAB27B SLC4A2 are upregulated in Bel/5Fu cells in accordance with the proteomics data. Moreover, cell viability assay and clonogenic survival assay results demonstrated that EPHX1 is closely related to the chemoresistance of Bel/5Fu to 5‐Fu. Conclusions and Clinical Relevance Plasma membrane protein EPHX1 is closely related to the chemotherapy resistance of Bel/5Fu cells and can be used as a new drug target to improve the clinical prognosis of patients with HCC.